A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study)

Japanese Journal of Clinical Oncology

Volumn 45, Issue 11, 2015, Pages 1082-1086

  Kataoka, Kozo ^a   Tokunaga, Masanori ^b   Mizusawa, Junki ^a   Machida, Nozomu ^b   Katayama, Hiroshi ^a   Shitara, Kohei ^c   Tomita, Toshihiko ^d   Nakamura, Kenichi ^a   Boku, Narikazu ^e   Sano, Takeshi ^f   Terashima, Masanori ^b   Sasako, Mitsuru ^d  

^a NATIONAL CANCER CENTER   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

HER2 positive gastric or esophagogastric junction adenocarcinoma; Randomized Phase II; SP plus trastuzumab

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DRUG COMBINATION; ERBB2 PROTEIN, HUMAN; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLINICAL PROTOCOL; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS SURGERY; GASTRECTOMY; HUMAN; JAPAN; JAPANESE (PEOPLE); LOWER ESOPHAGUS SPHINCTER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATICODUODENECTOMY; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; AGED; CHEMISTRY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL JUNCTION; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PATIENT SELECTION; PROCEDURES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; OXONIC ACID; PATIENT SELECTION; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TEGAFUR; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84949770483     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyv134     Document Type: Article

References (14)

1. Katayama H, Ito S, Sano T, et al. A Phase II study of systemic chemotherapy with docetaxel, cisplatin, and S-1 (DCS) followed by surgery in gastric cancer patients with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1002. Jpn J Clin Oncol 2012;42:556-9.
2. Tsuburaya A, Mizusawa J, Tanaka Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg 2014;101:653-60.
3. Yoshikawa T, Sasako M, Yamamoto S, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 2009;96:1015-22.
4. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376: 687-97.
5. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
8. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
9. Kurokawa Y, Sugimoto N, Miwa H, et al. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer 2014;110:1163-8.
10. Tokunaga M, Sugisawa N, Tanizawa Y, et al. The impact of preoperative lymph node size on long-term outcome following curative gastrectomy for gastric cancer. Ann Surg Oncol 2013;20:1598-603.
11. Nakamura K, Shibata T, Takashima A, et al. Evaluation of three definitions of progression-free survival in preoperative cancer therapy (JCOG0801-A). Jpn J Clin Oncol 2012;42:896-902.
12. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011;14:101-12.
13. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.
14. Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982;163-70.